Efficacy of a multistep strategy for Helicobacter pylori eradication

A. Gasbarrini, V. Ojetti, A. Armuzzi, G. Branca, F. Canducci, E. Sanz Torre, M. Candelli, A. Pastorelli, M. Anti, G. Fedeli, G. Fadda, P. Pola, G. Gasbarrini

Research output: Contribution to journalArticle

Abstract

Background: Helicobacter pylori eradication therapies do not achieve 100% success rates. Antibiotic resistant strains are among the major causes of failure. Current recommendations concerning the management of treatment failures are not fully clear. Aim: To evaluate the efficacy of a multi-step therapeutic strategy in a large group of infected patients. Methods: A total of 2606 H. pylori-positive patients were administered tinidazole, clarithromycin and a proton pump inhibitor for 1 week. Patients with continuing infection were then given a second 1-week course of amoxycillin, clarithromycin. and ranitidine bismuth citrate. Patients still infected after the second course underwent upper gastrointestinal endoscopy with H. pylori culture, and then received a 1-week quadruple proton pump inhibitor-bismuth based scheme established on H. pylori antibiotic sensitivity. Results: After the first step, eradication was achieved in 2063 out of 2413 patients [86% per protocol analysis (PP); 79% intention-to-treat analysis (ITT)]. First-step failures (350 out of 2413; 14.5% PP) showed second-step eradication rates of 82% (271 out of 329 patients, PP; 77% ITT). The specific quadruple therapy for second-step failures (58 out of 329, 18% PP) achieved 77% (30 out of 39 patients, PP) or 52% (ITT) success. This algorithm led to overall eradication rates of 99% (PP) or 91% (ITT). Conclusions: This multi-step strategy succeeded in a high percentage of H. pylori infected patients. Given the lack of precise guidelines on treatment failures, assessing H. pylori sensitivity to antibiotics only after failure of the second treatment could be suggested in clinical practice.

Original languageEnglish
Pages (from-to)79-83
Number of pages5
JournalAlimentary Pharmacology and Therapeutics
Volume14
Issue number1
DOIs
Publication statusPublished - 2000

Fingerprint

Helicobacter pylori
Intention to Treat Analysis
Treatment Failure
Clarithromycin
Proton Pump Inhibitors
Anti-Bacterial Agents
Tinidazole
Bismuth
Gastrointestinal Endoscopy
Amoxicillin
Therapeutics
Guidelines
Infection

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Gasbarrini, A., Ojetti, V., Armuzzi, A., Branca, G., Canducci, F., Torre, E. S., ... Gasbarrini, G. (2000). Efficacy of a multistep strategy for Helicobacter pylori eradication. Alimentary Pharmacology and Therapeutics, 14(1), 79-83. https://doi.org/10.1046/j.1365-2036.2000.00685.x

Efficacy of a multistep strategy for Helicobacter pylori eradication. / Gasbarrini, A.; Ojetti, V.; Armuzzi, A.; Branca, G.; Canducci, F.; Torre, E. Sanz; Candelli, M.; Pastorelli, A.; Anti, M.; Fedeli, G.; Fadda, G.; Pola, P.; Gasbarrini, G.

In: Alimentary Pharmacology and Therapeutics, Vol. 14, No. 1, 2000, p. 79-83.

Research output: Contribution to journalArticle

Gasbarrini, A, Ojetti, V, Armuzzi, A, Branca, G, Canducci, F, Torre, ES, Candelli, M, Pastorelli, A, Anti, M, Fedeli, G, Fadda, G, Pola, P & Gasbarrini, G 2000, 'Efficacy of a multistep strategy for Helicobacter pylori eradication', Alimentary Pharmacology and Therapeutics, vol. 14, no. 1, pp. 79-83. https://doi.org/10.1046/j.1365-2036.2000.00685.x
Gasbarrini, A. ; Ojetti, V. ; Armuzzi, A. ; Branca, G. ; Canducci, F. ; Torre, E. Sanz ; Candelli, M. ; Pastorelli, A. ; Anti, M. ; Fedeli, G. ; Fadda, G. ; Pola, P. ; Gasbarrini, G. / Efficacy of a multistep strategy for Helicobacter pylori eradication. In: Alimentary Pharmacology and Therapeutics. 2000 ; Vol. 14, No. 1. pp. 79-83.
@article{d724d758f32a47b588abd408d4f09c21,
title = "Efficacy of a multistep strategy for Helicobacter pylori eradication",
abstract = "Background: Helicobacter pylori eradication therapies do not achieve 100{\%} success rates. Antibiotic resistant strains are among the major causes of failure. Current recommendations concerning the management of treatment failures are not fully clear. Aim: To evaluate the efficacy of a multi-step therapeutic strategy in a large group of infected patients. Methods: A total of 2606 H. pylori-positive patients were administered tinidazole, clarithromycin and a proton pump inhibitor for 1 week. Patients with continuing infection were then given a second 1-week course of amoxycillin, clarithromycin. and ranitidine bismuth citrate. Patients still infected after the second course underwent upper gastrointestinal endoscopy with H. pylori culture, and then received a 1-week quadruple proton pump inhibitor-bismuth based scheme established on H. pylori antibiotic sensitivity. Results: After the first step, eradication was achieved in 2063 out of 2413 patients [86{\%} per protocol analysis (PP); 79{\%} intention-to-treat analysis (ITT)]. First-step failures (350 out of 2413; 14.5{\%} PP) showed second-step eradication rates of 82{\%} (271 out of 329 patients, PP; 77{\%} ITT). The specific quadruple therapy for second-step failures (58 out of 329, 18{\%} PP) achieved 77{\%} (30 out of 39 patients, PP) or 52{\%} (ITT) success. This algorithm led to overall eradication rates of 99{\%} (PP) or 91{\%} (ITT). Conclusions: This multi-step strategy succeeded in a high percentage of H. pylori infected patients. Given the lack of precise guidelines on treatment failures, assessing H. pylori sensitivity to antibiotics only after failure of the second treatment could be suggested in clinical practice.",
author = "A. Gasbarrini and V. Ojetti and A. Armuzzi and G. Branca and F. Canducci and Torre, {E. Sanz} and M. Candelli and A. Pastorelli and M. Anti and G. Fedeli and G. Fadda and P. Pola and G. Gasbarrini",
year = "2000",
doi = "10.1046/j.1365-2036.2000.00685.x",
language = "English",
volume = "14",
pages = "79--83",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "1",

}

TY - JOUR

T1 - Efficacy of a multistep strategy for Helicobacter pylori eradication

AU - Gasbarrini, A.

AU - Ojetti, V.

AU - Armuzzi, A.

AU - Branca, G.

AU - Canducci, F.

AU - Torre, E. Sanz

AU - Candelli, M.

AU - Pastorelli, A.

AU - Anti, M.

AU - Fedeli, G.

AU - Fadda, G.

AU - Pola, P.

AU - Gasbarrini, G.

PY - 2000

Y1 - 2000

N2 - Background: Helicobacter pylori eradication therapies do not achieve 100% success rates. Antibiotic resistant strains are among the major causes of failure. Current recommendations concerning the management of treatment failures are not fully clear. Aim: To evaluate the efficacy of a multi-step therapeutic strategy in a large group of infected patients. Methods: A total of 2606 H. pylori-positive patients were administered tinidazole, clarithromycin and a proton pump inhibitor for 1 week. Patients with continuing infection were then given a second 1-week course of amoxycillin, clarithromycin. and ranitidine bismuth citrate. Patients still infected after the second course underwent upper gastrointestinal endoscopy with H. pylori culture, and then received a 1-week quadruple proton pump inhibitor-bismuth based scheme established on H. pylori antibiotic sensitivity. Results: After the first step, eradication was achieved in 2063 out of 2413 patients [86% per protocol analysis (PP); 79% intention-to-treat analysis (ITT)]. First-step failures (350 out of 2413; 14.5% PP) showed second-step eradication rates of 82% (271 out of 329 patients, PP; 77% ITT). The specific quadruple therapy for second-step failures (58 out of 329, 18% PP) achieved 77% (30 out of 39 patients, PP) or 52% (ITT) success. This algorithm led to overall eradication rates of 99% (PP) or 91% (ITT). Conclusions: This multi-step strategy succeeded in a high percentage of H. pylori infected patients. Given the lack of precise guidelines on treatment failures, assessing H. pylori sensitivity to antibiotics only after failure of the second treatment could be suggested in clinical practice.

AB - Background: Helicobacter pylori eradication therapies do not achieve 100% success rates. Antibiotic resistant strains are among the major causes of failure. Current recommendations concerning the management of treatment failures are not fully clear. Aim: To evaluate the efficacy of a multi-step therapeutic strategy in a large group of infected patients. Methods: A total of 2606 H. pylori-positive patients were administered tinidazole, clarithromycin and a proton pump inhibitor for 1 week. Patients with continuing infection were then given a second 1-week course of amoxycillin, clarithromycin. and ranitidine bismuth citrate. Patients still infected after the second course underwent upper gastrointestinal endoscopy with H. pylori culture, and then received a 1-week quadruple proton pump inhibitor-bismuth based scheme established on H. pylori antibiotic sensitivity. Results: After the first step, eradication was achieved in 2063 out of 2413 patients [86% per protocol analysis (PP); 79% intention-to-treat analysis (ITT)]. First-step failures (350 out of 2413; 14.5% PP) showed second-step eradication rates of 82% (271 out of 329 patients, PP; 77% ITT). The specific quadruple therapy for second-step failures (58 out of 329, 18% PP) achieved 77% (30 out of 39 patients, PP) or 52% (ITT) success. This algorithm led to overall eradication rates of 99% (PP) or 91% (ITT). Conclusions: This multi-step strategy succeeded in a high percentage of H. pylori infected patients. Given the lack of precise guidelines on treatment failures, assessing H. pylori sensitivity to antibiotics only after failure of the second treatment could be suggested in clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=0033978868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033978868&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2036.2000.00685.x

DO - 10.1046/j.1365-2036.2000.00685.x

M3 - Article

C2 - 10632649

AN - SCOPUS:0033978868

VL - 14

SP - 79

EP - 83

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 1

ER -